Century Therapeutics (NASDAQ:IPSC) Lowered to Hold Rating by Leerink Partnrs

Leerink Partnrs downgraded shares of Century Therapeutics (NASDAQ:IPSC) from a strong-buy rating to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 20th. Leerink Partners reiterated a “market perform” rating and set a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.40.

Century Therapeutics Stock Up 1.7%

Shares of NASDAQ IPSC opened at $0.48 on Monday. The business has a 50-day moving average price of $0.54 and a 200 day moving average price of $0.55. The stock has a market cap of $41.93 million, a PE ratio of -1.50 and a beta of 1.80. Century Therapeutics has a 52-week low of $0.34 and a 52-week high of $1.83.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative return on equity of 10.01% and a negative net margin of 19.10%. Sell-side analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Century Therapeutics

Large investors have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new position in Century Therapeutics during the second quarter worth approximately $25,000. Qube Research & Technologies Ltd purchased a new position in shares of Century Therapeutics in the 2nd quarter worth about $38,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Century Therapeutics in the 2nd quarter valued at about $50,000. Raymond James Financial Inc. acquired a new stake in Century Therapeutics during the 2nd quarter worth approximately $51,000. Finally, AQR Capital Management LLC raised its holdings in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.